miR-24-mediated knockdown of H2AX damages mitochondria and the insulin signaling pathway

Jae Hoon Jeong, Young Cheol Kang, Ying Piao, Sora Kang and Youngmi Kim Pak

Mitochondrial deficits or altered expressions of microRNAs are associated with the pathogenesis of various diseases, and microRNA-operated control of mitochondrial activity has been reported. Using a retrovirus-mediated short-hairpin RNA (shRNA) system, we observed that miR-24-mediated H2AX knockdown (H2AX-KD) impaired both mitochondria and the insulin signaling pathway. The overexpression of miR-24 decreased mitochondrial H2AX and disrupted mitochondrial function, as indicated by the ATP content, membrane potential and oxygen consumption. Similar mitochondrial damage was observed in shH2AX-mediated specific H2AX-KD cells. The H2AX-KD reduced the expression levels of mitochondrial transcription factor A (TFAM) and mitochondrial DNA-dependent transcripts. H2AX-KD mitochondria were swollen, and their cristae were destroyed. H2AX-KD also blocked the import of precursor proteins into mitochondria and the insulin-stimulated phosphorylation of IRS-1 (Y632) and Akt (S473 and T308). The rescue of H2AX, but not the nuclear form of ΔC24-H2AX, restored all features of miR-24- or shH2AX-mediated impairment of mitochondria. Hepatic miR-24 levels were significantly increased in db/db and ob/ob mice. A strong feedback loop may be present among miR-24, H2AX, mitochondria and the insulin signaling pathway. Our findings suggest that H2AX-targeting miR-24 may be a novel negative regulator of mitochondrial function and is implicated in the pathogenesis of insulin resistance.

ORIGINAL ARTICLE

INTRODUCTION

In the last decade, deficits in mitochondrial function have been linked to nearly all age-associated degenerative diseases, including insulin resistance, metabolic syndrome and vascular complications of diabetes. Declines in oxidative phosphorylation (OXPHOS) or mitochondrial density have been observed in insulin-resistant individuals, the offspring of type II diabetic patients and even normal senescent subjects. Mitochondrial damage can be induced by genetic mutations and even normal senescent subjects. Mitochondrial damage can be induced by genetic mutations and various exogenous chemicals. However, the molecular mechanisms underlying the causes of mitochondrial dysfunction have not been clearly elucidated.

Mitochondria are dynamic organelles that are affected by mitochondrial DNA (mtDNA) and nuclear DNA (nDNA). Several nDNA-encoded factors control the expression of both mtDNA- and nDNA-encoded mitochondrial genes. Of these, the best-known genes are mitochondrial transcription factors A and B (TFAM and mtTFB), nuclear respiration factor-1 and -2 (NRF-1, NRF-2) and peroxisome proliferator-activated receptor γ coactivator-1α (PGC-1α). However, mitochondrial function is not always proportional to the expression level of these control factors. For example, mitochondrial density measured by electron microscopy is reduced in the skeletal muscles of the offspring of type II diabetic patients, but the expressions of PGC-1α, TFAM and NRF-1 are normal. This indicates that other factors may affect mitochondrial density or content. A wide range of proteomic, genomic and chemical approaches has been applied to identify novel mitochondrial modulators that are responsible for age- or disease-dependent changes, but so far, these entities remain unidentified.

We previously reported that histones were found in the mitochondrial proteome. H2A is an integral mitochondrial outer membrane protein with its N terminus protruding towards the cytoplasm. Here, we confirmed the mitochondrial localization of the H2A isoform H2AX. In the nucleus, H2AX has a critical role in DNA repair and genomic stability. Mice lacking H2AX show multiple phenotypic changes, including radiation sensitivity, growth retardation,
immune deficiency and male infertility. H2AX-deficient embryonic stem cells exhibit elevated levels of chromosomal aberrations. However, no function besides DNA repair and no location aside from the nucleus have previously been reported for H2AX.

H2AX has been reported as a target of microRNA-24. MicroRNAs (miRs) are potent post-transcriptional regulators of gene expression, but few targets or physiological implications of miRs have been analyzed in animals. Most miRs are functionally associated with developmental processes, such as morphogenesis, neurogenesis and developmental timing. In addition, the altered expression of specific miRs (miR-143, -29, -126, -143, -124) is involved in the pathogenesis of several human diseases, including obesity, diabetes, cancer, cardiac hypertrophy and neurodegeneration. In the present study, we found that miR-24 could negatively modulate mitochondrial function by targeting H2AX and consequently might be implicated in the development of diseases associated with mitochondrial dysfunction.

MATERIALS AND METHODS

Reagents

Dulbecco’s Modified Eagle’s Medium (DMEM) and fetal bovine serum (FBS) were purchased from Gibco-BRL (Grand Island, NY, USA). Dimethyl sulfoxide and all other chemicals were purchased from Sigma (St Louis, MO, USA). Double-stranded siRNAs targeting human H2AX (5′-caacaagaagcagacgtaacct-3′), miR-24 (hsa-miR-24, hsa-miR-24-3p, 5′-ggtccgtctgcaagcagacg-3′) and the scrambled control SCR (5′-aattctccgagcgtgcagct-3′) were synthesized by Samchulli, Seoul, Korea.

Cell culture and transient transfection

SK-Hep1 human hepatoma cells (ATCC, HTB-52) were cultured in Dulbecco’s Medium (DMEM) and fetal bovine serum (10% FBS, 100 U ml⁻¹ penicillin and 100 μg ml⁻¹ streptomycin) at 37 °C and 5% CO₂. For transient transfections, cells in 6-well plates (4×10⁵ cells per well) were transfected with synthetic siRNA (100 pmole) using the GeneJammer transfection reagent (Agilent, Santa Clara, CA, USA). Dimethyl sulfoxide and all other chemicals were purchased from Sigma (St Louis, MO, USA). Double-stranded siRNAs targeting human H2AX (5′-caacaagaagcagacgtaacct-3′), miR-24 (hsa-miR-24, hsa-miR-24-3p, 5′-ggtccgtctgcaagcagacg-3′) and the scrambled control SCR (5′-aattctccgagcgtgcagct-3′) were synthesized by Samchulli, Seoul, Korea.

Retroviral transduction of shRNAs for H2AX and miR-24

Double-stranded DNA oligonucleotides for miR-24 containing the BamH1-miR-24-Xhol loop-antisense miR-24-T5-EcoRI sequences (5′-gatcc ttgctcagtccagcgaacagtcttgaga gtaacctgtaacctgtaacctgttgggaag-3′) were cloned into the RNAi-Ready pSIREN-RetroQ vector (Clontech, Mountain View, CA, USA) to produce a retrovirus expressing miR-24 (Rv-miR-24) as short-hairpin RNA (shRNA) under the U6 promoter. Similarly, Rv-siRNA for H2AXi (Rv-shH2AX, 5′-gatcc caacaagaagcagacgtaacctcttgaga gtaacctgtaacctgttgggaag-3′) and scrambled control shRNAs (Rv-shSCR, 5′-gatcc aatctccgagcgtgcagcttgggaagttgggaag-3′) were produced. The BD RetroPack PT67 packaging cells (BD Biosciences, Billerica, MA, USA) were treated for 5 min with 25 μM chloroquine (Sigma) and transfected with 3 μg pSIREN-RetroQ-shRNA using the GeneJammer transfection reagent. At 48 h post-transfection, the virus population in the supernatant was harvested by filtration through a 0.45-μm syringe filter and centrifugation at 50,000 × g for 1.5 h. The pelleted virus was resuspended in one-tenth of the original volume of medium and incubated at 4 °C for several hours. To establish stably Rv-shRNA-infected cells expressing miR-24, shH2AX or shSCR, SK-Hep1 cells (0.8 × 10⁶/ml-mm plate) were infected with the recombinant retrovirus (1 × 10⁵ pfu/ml -1 final concentration) and selected in media containing puromycin (1 μg ml⁻¹) for 2 weeks.

Cell number

Cell numbers were determined using the Imagel program. Briefly, cells were cultured on poly-L-lysine coated-cover slips in 6-well plates for various time periods. Then, the cells were stained with 2 μg ml⁻¹ Hoechst 33342 for 10 min, fixed with 4% paraformaldehyde for 15 min and permeabilized with 0.1% Triton X-100 for 10 min at room temperature. After washing with PBS, the coverslips were mounted with GEL/MOUNT (Biomeda, Foster city, CA, USA), and the fluorescence was visualized under a fluorescence microscope (Leica DMIRE, Ontario, NY, USA). The number of Hoechst-positive cells was counted automatically in 10 different areas (0.8 mm² per area) using ImageJ.

Mitochondrial activity assays

The mitochondrial activity of the stably expressing cells was analyzed using a 96-well plate as described previously. The quantitative measurements of the lactate dehydrogenase (LDH) activity, lactate concentration, the pH of media, tetramethylrhodamine ethylester (TMRE, Molecular Probes, Eugene, OR, USA)-mediated mitochondrial membrane potential (ΔΨm), the 5,6-chloromethyl-2′, 7′-dichlorofluorescin diacetate (CM-DCF-DA, Molecular Probes)- and MitoSox-mediated ROS content, Oxyblot and intracellular ATP content were probed. Briefly, cells (3 × 10⁴ cells) were cultured for up to 72 h in 6-well plates with a medium change every 24 h. The LDH activity was measured using the TOX7 LDH assay kit (Sigma). The lactate concentration and culture media pH were measured using a lactate assay kit (BioVision, Mountain View, CA, USA) and a pH meter, respectively. Cells cultured in black 96-well culture plates were incubated with 200 nM TMRE or Hoechst 33342 (0.5 μM) at 37 °C for 30 min in phenol red-free SDM. The mitochondrial superoxide levels were measured after incubating cells with 5 μM MitoSox (Molecular Probes) for 10 min at 37 °C, and the samples were protected from light. The cells were washed with PBS and counterstained with 2 μg ml⁻¹ Hoechst 33342 for 10 min, and the fluorescence intensities were determined at 510/580 nm. The MitoSox intensity was normalized to the Hoechst intensity. The extent of protein oxidation was assessed by measuring the carbonyl protein levels with an OxyBlot protein oxidation detection kit (Chemicon International, Temecula, CA, USA). The data are expressed as the means ± s.e. of three independent experiments.

Oxygen consumption rate measurements

The oxygen consumption rate (OCR) of each OXPHOS complex was measured using Oxygraph-2 K (Oroboros, Innsbruck, Austria) as described previously. Cells were collected by trypsinization and resuspended in 1 ml of respiration media containing 100 μM p1, p5-di (adenosine)-5′-pentaphosphate and an adenosine kinase inhibitor. The cells (6 × 10⁶) were permeabilized with 10 μg ml⁻¹ digitonin in

Experimental & Molecular Medicine
the Oxygraph-2 K chamber. The OCRs were determined as OXPHOS complex inhibitors and substrates were sequentially added as follows: 2 mM ADP, 8 mM malate and 20 mM glutamate for complex I; 1 μM rotenone, 10 mM succinate and 2.5 μM glycerol-3-phosphate for complexes II and III; 25 μM antimycin A, 80 μM ascorbate and 0.42 mM N,N,N,N-tetramethyl-p-phenylenediamine (TMPD) for complex IV; and 2.5 mM KCN for KCN-insensitive respiration.

The respiratory capacity and ATP turnover rate were determined using a Seahorse XF-24 analyzer (Seahorse Bioscience, Billerica, MA, USA). Cells (5×10^3 cells per well) were seeded in XF-24 microwell plates in 250 μL DMEM containing 10% FBS and incubated at 37 °C/5% CO₂ for 24 h. The assays were initiated by replacing the medium in each well with 590 μL assay medium (DMEM without sodium bicarbonate) pre-warmed to 37 °C. After gentle mixing for 10 min in the XF-24 Analyzer, the basal OCR was measured for 3 min. Oligomycin (65 μL of 10 μg ml⁻¹ stock), carbonyl-cyano-p-trifluoromethoxyphenylhydrazone (FCCP, 73 μL of 3 μM stock) and rotenone (81 μL of 1 μM stock) were consecutively injected into each well to reach the desired final working concentration for quantifying the ATP turnover rate (basal OCR—oligomycin-OCR) and respiratory capacity (FCCP-OCR—rotenone-OCR). The OCR was calculated from 3-min measurement cycles. The respiration results were normalized to the cell number.43

Western blot analysis

Protein extracts were prepared from the cells using PRO-PREP lysis buffer (10 mM HEPES, pH 7.9, 10 mM KCl, 2 mM MgCl₂, 0.5 mM dithiothreitol, 1 mM phenylmethylsulfonyl fluoride, 5 μM aprotinin, 5 μM pepstatin A, 5 μM leupeptin and 1% Triton X-100; iNtRON Biotech, Gyeonggi-do, Korea). A total of 25 μg of protein extract was separated on 12% SDS gels and analyzed using an enhanced chemiluminescence system (Amersham Bioscience, Piscataway, NJ, USA). The H2AX-specific antibodies against mouse H2AX (R&D Systems, Minneapolis, MN, USA), H2A, H2B, PGC-1α (Santa Cruz Biotechnology, Santa Cruz, CA, USA), Akt1, pAKT, FOXO1, pFOXO1, AMPK, pAMPK (Cell Signaling Technology, Beverly, MA, USA), ND9, SDHA, UQCR10, COXI, COXIV and ATPase α (Molecular Probes) were purchased from commercial sources as indicated. The rabbit polyclonal antibodies against human TFAM, NRF-1 and human H2AX were prepared in our laboratory.8 The H2AX-specific tail peptide (PKAPSGGKKAQASQE) was synthesized and conjugated with keyhole limpet hemocyanin to prepare the human H2AX antibody.44 An equivalent protein loading was verified using anti-β-actin antibodies (Sigma).

RNA preparation, semi-quantitative RT-PCR and real-time qPCR

The total RNA was isolated using the TRIzol reagent (Invitrogen, Carlsbad, CA, USA). The total RNA (2 μg) was reverse transcribed using MMLV reverse transcriptase (Promega, Madison, WI, USA) and 250 ng of random primers (Invitrogen) according to the manufacturer’s instructions. Real-time quantitative PCR was performed using the primers for H2AX (5′-cat gtc ggg ccc cag caa-3′ and 5′-ggt ggg cct tgc ttc tgg-3′) for human H2AX; 5′-ggc ctg tgg aca gtt cta t-3′ and 5′-ggc cat taa atc ttc cca c-3′ for mouse H2AX) or 18S RNA (5′-gag cca aag cat tgc tgg cca agg-3′ and 5′-ggt ggc atc gtt tat agg cgg caa-3′) for both human and murine 18S rRNA) on a Light Cycler 1.5 (Roche, Indianapolis, IN, USA) with SYBR Premix Ex Taq (TaKaRa, Shiga, Japan) at 95 °C for 10 s, followed by 40 cycles of 95 °C for 5 s and 60 °C for 34 s. The measurements were performed in duplicate for each sample. The H2AX mRNA quantity was corrected by the simultaneous measurement of nuclear DNA encoding 18S rRNA. The relative quantification of gene expression was determined using the 2−ΔΔCt method. The relative miRNA expression levels were presented as fold changes compared with that of the control condition.

We also carried out semi-quantitative RT-PCR to quantify the expression levels of mitochondria-related genes, including 13 mtDNA-encoded OXPHOS subunits, the nDNA-encoded OXPHOS subunits and the mitochondrial biogenesis controlling proteins. PCR products of these genes did not reach saturation levels within the cycle limits. The reaction products were examined using 1.2% agarose gel electrophoresis and normalized to the RT-PCR products for 18S rRNA. The presence of mtDNA was verified by PCR using a genomic DNA template and two different sets of primers, and the results were normalized to β-actin DNA. The primer information for RT-PCR and PCR is summarized in Supplementary Table 1.

The total RNA containing microRNAs was purified using the mirNeasy Mini Kit (Qiagen, Hilden, Germany). The reverse transcription of miRNA into cDNA was performed using the miScript Reverse Transcription Kit. The amount of miR-24 was quantified by real-time PCR performed on a Rotor-Gene Q cycler (Qiagen) using the miScript Primer Assay and miScript SYBR Green PCR Kits (Qiagen). The specific primer sets for quantification, MS0001827 for mir-24 and MS00033740 RNU6 control for normalization, were purchased from Qiagen.

Transmission electron microscopy

For morphological assessment of the mitochondria, the cell suspensions were fixed with 2% paraformaldehyde and 2% glutaraldehyde in 50 mM sodium cacodylate buffer (pH 7.2) for 4 h and washed with the same buffer. All specimens were exposed to 1% osmium tetroxide in 50 mM sodium cacodylate buffer (pH 7.2) for 2 h at 4 °C, rinsed, dehydrated with ethanol and flat-embedded in Spurr’s embedding media. Ultrathin sections were stained with 2% uranyl acetate and Reynolds’ lead citrate and then examined by transmission electron microscopy at 80 kV (JEM-1011, JEOL, Tokyo, Japan).45

Immunocytochemistry

Cells grown on glass coverslips were stained with MitoTracker Orange (Mito-T, Molecular Probes) at 300 nM for 20 min in complete medium containing 10% FBS. The cells were fixed for 5 min in 4% paraformaldehyde/PBS and permeabilized with ice-cold 0.1% Triton X-100 for 10 min. The cells were then covered with 5% BSA in Tris-buffered saline for 30 min at room temperature followed by incubation with the anti-H2AX antibodies (1:500, Cell Signaling Technology) for 1 h. After washing, the cells were probed with the appropriate secondary antibodies conjugated to Alexa Fluor 488 (1:1,000, Molecular Probes) for 1 h. The slides were then washed twice with PBS and mounted using DAKO fluorescent mounting medium (DAKO Corporation, Carpenteria, CA, USA). The specimens were viewed using a laser scanning confocal microscope (Carl Zeiss LSM510, Zena, Germany).

Luciferase assay for miR-24 target specificity

The short form (661 bp) of the human H2AX 3′-UTR46 was amplified by RT-PCR from the total RNA isolated from SK-HeP1 cells using the primers 5′-gacggagactcaaca-3′ and 5′-gtagatcgaaga-3′. To produce the construct pCMV-luc-H2AX-3′-UTR (Luc-H2AX-3′-UTR, full), the
664-bp PCR fragment of H2AX 3′-UTR was cloned into the XbaI site after the luciferase stop codon of pCMV-luc (a gift from Dr VN Kim, Seoul National University, Korea). Three different H2AX 3′-UTR fragments containing one of three putative miR-24 binding sites (MBS-A, B and C) were generated by PCR using Luc-H2AX-3′-UTR (full) and cloned into pCMV-luc to produce pCMV-luc-A, -B or -C (Luc-H2AX-3′-UTR: A, B, C). SK-Hep1 cells in 6-well plates were transiently co-transfected with the pSIREN-RetroQ plasmids (2 μg) containing either shSCR (pS-shSCR) or miR-24 (pS-miR-24) together with pCMV-luc (Luc, 100 ng) or Luc-H2AX-3′-UTR (100 ng) using the GeneJammer transfection reagent. The cells were harvested after 24 h of incubation in DMEM supplemented with 10% FBS and assayed for luciferase activity using a luciferase assay kit (Promega, Madison, WI, USA) and a luminometer (Berthold, Badwildbad, Germany). Because the LacZ vector (200 ng) was co-transfected with the reporter, the transfection efficiencies were normalized to β-galactosidase activity. All assays were performed in triplicate in three independent experiments.

Co-immunoprecipitation

Antibodies against TOM20 or H2AX were cross-linked to Protein A/G PLUS-Agarose beads (Santa Cruz Biotechnology) using dimethyl pimelimidate (Pierce, Rockford, IL, USA) according to the manufacturer’s instructions. Cell lysates (500 μg) in IP buffer (50 mM Tris, pH 8, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100, 1 mM PMSF, 2 μg ml⁻¹ leupeptin, 1 μg ml⁻¹ pepstatin and 2 μg ml⁻¹ aprotinin) were precleared with 1 μg of normal IgG for 1 h at 4 °C and incubated with TOM20- or H2AX-conjugated agarose beads under constant rotation overnight at 4 °C. The slurry was washed with IP buffer, boiled in 40 μl IP buffer and 10 μl SDS-PAGE loading buffer, and subjected to western blot analysis.

Mitochondrial protein import assay using isolated mitochondria

Mitochondria were isolated from cultured cells by differential centrifugation. Two different DsRed2 fusion constructs were cloned into a pcDNA3.1(+) vector under control of the T7 promoter.

Figure 1 Specific knockdown of human H2AX by miR-24. (a) Co-immunostaining of H2AX with the mitochondrial transporter TOM20 in SK-Hep1 cells. H2AX is present in the cytoplasm and is partially co-localized with TOM20 in the mitochondria. The area in the white rectangle is enlarged at the bottom of each picture. Scale bar = 20 μm (top) or 5 μm (bottom). (b) Co-immunoprecipitation of H2AX and TOM20. SK-Hep1 cells were immunoprecipitated (IP) with antibodies against H2AX or TOM20 that were cross-linked to Protein A/G beads. The eluted proteins were analyzed by western blot (WB) with antibodies against TOM20 or H2AX. (c) WB of whole-cell lysates from the stably Rv-shRNA-infected cells, using the anti-H2AX or pan-H2A antibody. shSCR, Rv-shRNA containing scrambled control siRNA; shH2AX, Rv-shRNA containing H2AX siRNA; miR-24, Rv-shRNA containing miR-24. (d) Real-time qRT-PCR of H2AX mRNA in stably Rv-shRNA-infected cells. The mRNA level was normalized by 18S rRNA. (e) Real-time qRT-PCR of miR-24 in stably Rv-shRNA-infected cells. The miR-24 level was normalized by U6 snRNA. (f) WB of organelle fractions from the stably Rv-shRNA-infected cells. Nuc, nuclei; Mito, mitochondria. Hsp60 and cytochrome c (Cyto C) are markers for the mitochondria and PARP is a nuclear marker. β-actin was used as a loading control. (g) Confocal images of the stably Rv-shRNA-infected cells. Cells were stained with Mitotracker (Mito-T, red), fixed and then stained with the anti-H2AX antibody (green). Box (miR-24 enhanced): the same miR-24 cells were exposed to 10-fold stronger laser excitation for better visualization. Scale bar = 50 μm.
MTS-DsRed2 protein (28.5 kDa) is DsRed2 conjugated to the 35-amino acid MTS of succinate dehydrogenase complex subunit C. H2AX-DsRed2 (41 kDa) is a fusion protein of H2AX at the N terminus of DsRed2. Both DsRed2 fusion proteins were synthesized using the TNT Coupled Reticulocyte Lysate System (Promega) according to the manufacturer’s instructions. An in vitro import assay of hybrid proteins containing DsRed2 was performed as previously described.44 Briefly, we incubated newly in vitro-synthesized fusion proteins (3.75 μl in 50 μl TNT mixture) with 75 μg of mitochondria in 12.5 μl mitochondria isolation buffer (0.025 M Tris HCl, pH 7.4, 0.25 m sucrose and 1 mM EDTA) in 50 μl import assay buffer (50 mM HEPES, 0.47 mM sucrose, 2.5 mM DTT, 2.5 mM MgCl2, 250 mM KCl, 1 mM ATP and 5 mM phosphoenolpyruvate) with 6.25 units of pyruvate kinase at 30 °C for 30 min. The assay mixture was divided into two aliquots and treated with or without proteinase K (0.2 mg ml\(^{-1}\) final concentration) for 30 min on ice. Mitochondria treated with FCCP (2 μM) were used as a negative control. The harvested mitochondria were subjected to 10% SDS-PAGE, and the imported fusion proteins were visualized by immunoblotting using anti-DsRed2 antibodies (Santa Cruz Biotechnology). Western blot analysis of H2AX and Hsp60 was performed to assess the presence of H2AX and equal mitochondrial loading, respectively.

Animals
Diabetic (db/db), obese (ob/ob) and control lean mice (C57BL/6, male, 15 weeks old, \(n=7\) per group) were purchased from Orient-Bio, Korea and Shizuoka Laboratory Center, Hamamatsu, Japan. All animals were killed in the morning after a 1 week quarantine period, and the tissues were collected, frozen in liquid nitrogen and stored at \(-80^\circ\text{C}\). The hepatic expression levels of H2AX and miR-24 were analyzed by western blot and real-time qPCR. All animal procedures were performed in accordance with the guidelines set forth by the Kyung Hee University Council Directive for the Proper Care and Use of Laboratory Animals.

Statistical analysis
All results are expressed as the mean±s.e. of the mean. Statistical differences between experimental groups were assessed by Student’s \(t\)-tests using InStat (GraphPad Software, San Diego, CA, USA). Values of \(P<0.05\) were considered statistically significant.

RESULTS
Knock down of mitochondrial H2AX by miR-24 or shH2AX
Immunostaining verified the mitochondrial localization of H2AX (Figure 1a). H2AX was co-immunoprecipitated with the mitochondrial transporter TOM20, showing their presence in a complex (Figure 1b). To investigate the role of H2AX in mitochondria, we applied a retroviral system expressing a short-hairpin RNA (Rv-shRNA) to deliver miR-24 or shH2AX inside cells for silencing H2AX. The miRNA miR-24 effectively reduced H2AX to a similar degree as shH2AX.

![Figure 2](image-url) Target specificity of miR-24 and shH2AX. (a) Diagram of the two different forms of H2AX 3′-UTR. Locations of three MBSs (A, B, C) in the 3′-UTR of H2AX are depicted by arrows (red). Both the long (upper figure) and short 3′-UTR (lower figure) contain all three MBSs. (b) Putative binding schemes of miR-24. MBS-A and MBS-C are targets of miR-24 (red). MBS-B is a target of antisense miR-24 (blue). (c) SK-Hep1 cells were co-transfected with LacZ (β-gal) and pSIREN-RetroQ plasmids containing shSCR (pS-shSCR) or miR-24 (pS-miR-24) together with pCMV-luc (Luc) or four different pCMV-luc-H2AX-3′-UTRs (Luc-H2AX-3′-UTR) containing full-length (Full), MBS-A, MBS-B or MBS-C of the H2AX 3′-UTR. The luciferase activities were normalized to the β-gal activity. The data show the mean±s.e. of three independent duplicate experiments (\(n=6\)). (d) SK-Hep1 cells expressing GFP or H2AX-GFP chimeric protein were infected with Rv-shSCR or Rv-shH2AX and selected using 1 μg ml\(^{-1}\) puromycin. The confocal images of the stably expressing cells showed the specific knockdown of H2AX-GFP by shH2AX. Scale bar = 50 μm.
Stably Rv-shRNA-infected cells had persistently decreased H2AX expression throughout the culture period without reducing the total H2A level (Figure 1c). In those cells, the H2AX mRNA levels were decreased by ~30–50%, suggesting that miR-24 mediated the degradation of H2AX mRNA in addition to halting translation (Figure 1d). The level of miR-24 experienced a 2-fold increase in miR-24 cells but a 40% decrease in shH2AX cells (Figure 1e). Because H2AX is present in both nuclei and mitochondria, we verified which H2AX was knocked-down by immunocytochemical staining and organelle fractionation. Both miR-24 and shH2AX suppressed the amount of H2AX protein in both organelles (Figure 1f).

Importantly, we note here that MitoTracker (Mito-T) staining was significantly reduced in both H2AX knock down (KD) cells, and some miR-24 cells were much larger than shSCR- or shH2AX-cells (Figure 1g).

The target specificity of shH2AX and miR-24 was verified using a GFP-H2AX fusion protein and a luciferase reporter carrying the 3′-UTR of H2AX (Figure 2). It has been reported that there are two different lengths of H2AX 3′-UTR transcripts (Figure 2a). Importantly, both the long (1148 bp) and short (661 bp) 3′-UTRs contain all three predicted miR-24 binding sequences (MBS), which were designated A, B and C. Putative binding schemes of miR-24 to each of the MBS locations are presented in Figure 2b. We predicted that the miR-24 guide strand targeted MBS-A and MBS-C of the H2AX 3′-UTR, whereas the miR-24 passenger strand targeted MBS-B. We constructed luciferase reporter plasmids containing the 661 bp H2AX 3′-UTR (Full) or each of the three MBS sites (A, B, C) at the 3′-end of the luciferase gene in a modified pGL3 vector (pCMV-luc, Luc). Then, co-transfection of the overexpression plasmids for either shSCR (pS-shSCR) or miR-24 (pS-miR-24), along with the luciferase reporters, was performed. The luciferase activity of all four Luc-H2AX-3′-UTR constructs was significantly decreased by pS-miR-24, demonstrating that miR-24 specifically targeted all three binding sites in the H2AX 3′-UTR (Figure 2c). The H2AX-GFP fluorescence intensity of the stably expressing cells that overexpress H2AX-GFP fusion protein was specifically decreased after infection with Rv-shH2AX (Figure 2d).

Mitochondrial dysfunction in two groups of H2AX-KD cells

In addition to impairments in DNA repair, growth retardation, immune deficiency and male infertility have been reported in

![Figure 3](Image)
H2AX knock-out mice. Thus, we first assessed the growth rates of two populations of H2AX-KD cells. The proliferation rate of miR-24 and shH2AX cells were ~40–50% lower than that of shSCR control cells (Figure 3a). Both sets of cells showed an incubation time-dependent increase in LDH activity (Figure 3b) and acidification of the media pH (Figure 3c), suggesting that a blockage of mitochondrial function might induce anaerobic glycolysis. In fact, miR-24 and shH2AX was decreased >50% of the OCR by four OXPHOS complexes (Figure 3d), and they also reduced the TMRE-based mitochondrial membrane potential (ΔΨm) and intracellular adenosine-5'-triphosphate (ATP) content up to 60–70% (Figure 3e). When mitochondria become damaged, electrons leaking from the OXPHOS complex react with oxygen to produce reactive oxygen species (ROS). As expected, miR-24- or shH2AX-induced H2AX-KD enhanced productions of DCF-DA-ROS and MitoSox-mitochondrial superoxides (Figure 3f) and the levels of oxidized (carbonylated) proteins, as shown by Oxyblot (Figure 3g). We noted here that the characteristics of miR-24 cells were similar to those of shH2AX cells, a specific knockdown of H2AX, in most assayed aspects. This means that the major target of miR-24 should be H2AX.

Alterations in mitochondrial gene expressions and morphology of H2AX-KD cells

Next, we performed semi-quantitative reverse transcription-polymerase chain reaction (semi-qRT-PCR) or western blot analyses for 13 mtDNA-encoded OXPHOS genes (mtOXPHOS), 10 nDNA-encoded OXPHOS genes (nuOXPHOS) and 6 mitochondrial control genes. The miRNA miR-24 almost abolished the transcripts of all mtOXPHOS genes, and shH2AX decreased the levels of most of them (Figure 4a). However, the effects of miR-24 and shH2AX on nDNA-encoded genes were varied. They either reduced the transcripts of nuOXPHOS (UQCRB, COX5B, COX7B, ATP5A1, ATP5O) or mitochondrial control genes (NRF-1, TFAM, UCP2) or did not affect other genes (NDUFA6, NDUFB9, SDHC, PGC-1α, SOD2) (Figure 4b). Western blotting showed that miR-24 and shH2AX resulted in a specific decrease in the expression of COX I and ATPase α, but not in the expression of ND9, SDHA and COX IV (Figure 4c). Among the tested mitochondrial control proteins, only TFAM showed a severe decrease in both mRNA and protein levels (Figures 4b and d). As TFAM decreased, the mtDNA copy numbers were also reduced (Figure 4e). When the morphology and density of the mitochondria were examined using transmission electron microscopy, the mitochondria of shH2AX and miR-24 cells appeared round, swollen and less electron dense compared with control cells (Figure 4f), which is similar to other mtDNA-depleted cells.48

H2AX, but not ΔC24-H2AX, rescued the mitochondrial defects

We next tested whether H2AX deficiency is solely responsible for the miR-24-induced mitochondrial damage by performing rescue experiments. We stably transfected pcDNA3.1-H2AX into shH2AX- or miR-24-cells and confirmed the successful rescue of H2AX expression (Figures 5a and b; Supplementary Figure 1a). The H2AX-rescued cells showed normal mitochondrial morphology in EM images (Figure 5c). They also had restored FCCP-induced respiratory capacity and an oligomycin-mediated ATP turnover rate at normal levels (Figure 5d).

As H2AX does not contain a notable MTS and the C-terminus is responsible for mitochondrial transport,20 we constructed the nuclear form of H2AX instead of the mitochondrial form of H2AX. A C-terminally truncated form of H2AX (deletion of 24 amino acids from 120-143, ΔC24) was localized only in the nucleus and not in the mitochondria.20 ΔC24 was used as nuclear H2AX. The overexpression of ΔC24 failed to restore intracellular ATP content, ΔΨm (TMRE), DCF-DA-mediated ROS and lactic acids to normal levels (Figures 5e and f; Supplementary Figure 1b). These results indicated that only mitochondrial H2AX, but not nuclear H2AX, was responsible for modulating mitochondrial activities.

Deficient protein import of mitochondria isolated from H2AX-KD cells

Two important issues that needed to be resolved were the mechanism by which H2AX is transported into the mitochondria, as H2AX does not contain a notable mitochondrial-targeting sequence (MTS), and how H2AX controls mitochondrial activities. Because mitochondrial H2AX (mtH2AX) forms a complex with TOM20 on the mitochondrial surface, we hypothesized that mtH2AX might be involved in the mitochondrial import of cytoplasmic precursor proteins. The conventional mitochondrial import assay was not possible because the H2AX protein does not contain the amino acids for proper labeling. Instead, we constructed two different artificial mitochondrial precursor proteins fused to theDsRed2 fluorescent protein, MTS-DsRed2 (28.5 kDa) and H2AX-DsRed2 (41 kDa). Mitochondria isolated from shSCR-, shH2AX- or miR-24-cells were incubated with the newly synthesized fusion proteins. The DsRed2 proteins that were transported into mitochondria were analyzed by immunoblotting of the re-isolated mitochondria (Figure 6a). Both MTS-DsRed2 and H2AX-DsRed2 were transported into control shSCR-mitochondria, processed and protected from protease K digestion. MTS-DsRed2 import into either shH2AX- or miR-24-mitochondria was completely abolished, and H2AX-DsRed2 import was reduced up to 80%. The molecular weight of protease K-resistant DsRed2 in H2AX-DsRed2 import was approximately 26 kDa, indicating that H2AX was removed from the fusion protein in the mitochondria. The FCCP-treated mitochondria completely lost its mitochondrial import capability. We concluded that shH2AX- and miR-24-mitochondria should be defective in the import of nuclear-encoded proteins, such as TFAM and H2AX.
**Figure 4** H2AX knockdown disrupted mitochondrial mRNA/protein expression and the mitochondrial ultrastructure. (a, b) Semi-quantitative RT-PCR of mRNA in the stably Rv-shRNA-infected cells cultured for 24 h in complete media. (a) 13 mtDNA-encoded OXPHOS subunits, (b) 10 nuclear DNA-encoded OXPHOS subunits and 6 mitochondrial biogenesis control genes. All data are presented as the mean ± s.e. (n = 4). (c, d) Western blot analysis of the OXPHOS subunits (c) and mitochondrial biogenesis control proteins (d). (e) Quantification of mtDNA. The mtDNA regions encoding COXI (106 bp) or the D-loop region (410 bp) were PCR-amplified from genomic DNA. (f) Electron micrographs of the mitochondria. The designated stably Rv-shRNA-infected cells were fixed and examined by electron microscopy at magnifications of ×6000 (Scale bar = 2 μm) and ×50,000 (Scale bar = 0.5 μm).
In addition, H2AX itself is able to translocate the DsRed2 cargo protein into the mitochondria.

Insulin signaling pathway defects in H2AX-KD cells
To investigate whether H2AX-KD-mediated mitochondrial dysfunction altered the insulin signaling pathway, we determined the phosphorylation state of insulin signaling molecules in these cells with or without insulin stimulation. The overexpression of miR-24 or shH2AX repressed insulin-stimulated pIRS-1(Y632), pAkt(T308), pAkt(S473) and pFoxO1(S256) to similar degrees (Figure 6b). In these stably expressing cells, pAMPK(T172) was enhanced independently of insulin stimulation, implying that H2AX-KD-mediated mitochondrial dysfunction might constitutively activate AMPK. However, the AMPK activation was not enough to recover the mitochondrial damage. The results suggested that the miR-24- or shH2AX-induced mitochondrial damage may block the phosphorylation of Akt and IRS-1 in the insulin signaling pathway, similar to insulin resistance. This agrees with our previous report showing the cross-talk between IRS-1/Akt and the mitochondria.4,8,42 The toxin-induced mitochondrial deficits suppressed the phosphorylation of Akt and IRS-1. The present results confirmed that IRS-1 and Akt might be the cross-talk points between insulin signaling and mitochondrial dysfunction.

Hepatic H2AX was reduced in diabetic and obese mice
To validate the roles of H2AX and miR-24 in disease models, we determined the levels of H2AX and miR-24 expression in diabetic (db/db) and obese (ob/ob) mouse livers. Although these mice are leptin receptor- or leptin-deficient genetic models, they show hepatic insulin resistance and mitochondrial dysfunction.49–52 Western blots of H2AX revealed that the H2AX protein levels were decreased, and the real-time qPCR of miR-24 showed the miR-24 levels were increased in these mice (Figure 6c).
Considering our data, we thought that the enhanced miR-24 expression may suppress H2AX, leading to mitochondrial import deficiency. Blocking the transport of mitochondrial proteins into the mitochondria, including TFAM, may aggravate mitochondrial damage, resulting in the inactivation of insulin signaling at Akt and IRS-1. The possible connections among the proteins are summarized in Figure 6d.

**DISCUSSION**

The present study demonstrated novel functions of mitochondrial H2AX and its post-transcriptional regulator miR-24 in the regulation of mitochondrial activity. Specifically, mitochondrial H2AX is involved in the import of precursor proteins into the mitochondria. The increased expression of miR-24 eliminated mitochondrial H2AX, leading to defects in mitochondrial protein import. Insufficient TFAM transport subsequently induced mitochondrial damage in a feedback loop, as depicted in Figure 6d.

The term 'mitochondrial H2AX (mtH2AX)' may be confusing because mitochondria have been previously thought to be histone-free organelles. As mtH2AX does not bind to mtDNA in the mitochondrial matrix, the biological role of mtH2AX was considered to be distinct from the DNA repair activity of H2AX in the nucleus. Instead, mtH2AX binds to TOM20, a component of the mitochondrial import machinery, and has a critical role in the post-translational transport of mitochondrial precursor proteins into the mitochondria (Figure 6a). Our results demonstrated that both shH2AX and miR-24 primarily suppressed mtH2AX and inhibited the mitochondrial transport of the cargo protein DsRed2 ligated to MTS or H2AX in vitro (Figure 6a). Among the nDNA-encoded mitochondrial proteins tested, the most affected were TFAM and ATPase α (Figure 4). It is likely that the downregulation of TFAM in
miR-24 is upregulated by exogenous stimuli, such as phorbol ester, ROS (H2O2) or hemin.4,5 Various sources of mitochondrial damage ranging from DNA mutations to environmental toxins block electron transfer through OXPHOS complexes and induce profound ROS generation. It is reasonable to suggest that mitochondrial damage-induced ROS leads to miR-24 upregulation. A balance may be present among miR-24, H2AX, mitochondria, insulin signaling and obesity that is interconnected. Thus, if one of these factors is disturbed, it will cause an imbalance in the whole cycle, which will become progressively aggravated in the absence of intervention.

Multiple studies have shown that deficiencies of mtDNA or TFAM in various tissues can cause a wide range of diseases, depending on tissue type. However, it is not understood why mitochondrial activities are decreased in patients with metabolic diseases and in normal senescent subjects. Our data imply that miR-24 and mtH2AX may be the missing link between mitochondrial dysfunction and insulin resistance. The reduction of mitochondrial function through the upregulation of miR-24 and a decrease in H2AX might result in the development of metabolic disorders in senescent subjects. Collectively, we hypothesize that miR-24 and H2AX might be novel therapeutic targets for age-related diseases associated with mitochondrial dysfunction.

CONFLICT OF INTEREST

The authors declare no conflict of interest.

ACKNOWLEDGEMENTS

We thank Tong-Kon Yu (University of Ulsan, Korea) for excellent technical assistance. This study was supported by a grant (HI14C2700) from the Korean Health Technology R&D Project, Ministry of Health & Welfare and partly by a grant (10051960) from the Technology Innovation Program from the Ministry of Trade, Industry & Energy of Korea.

Author contributions: JHJ, YCK, YP and SK planned and performed the experiments, and analyzed the data. YKP supervised the project, designed the experiments and wrote the manuscript with comments from the coauthors. All authors collaborated on the work.

1 Park KS, Nam KJ, Kim JW, Lee YB, Han CY, Jeong JK et al. Depletion of mitochondrial DNA alters glucose metabolism in SK-Hep1 cells. *Am J Physiol Endocrinol Metab* 2001; 280: E1007–E1014.
2 Song J, Oh JY, Sung YA, Pak YK, Park KS, Lee HK. Peripheral blood mitochondrial DNA content is related to insulin sensitivity in offspring of type 2 diabetic patients. *Diabetes Care* 2001; 24: 865–869.
3 Petersen KF, Befroy D, Dufour S, Dziura J, Ariyan C, Rothman DL et al. Mitochondrial dysfunction in the elderly: possible role in insulin resistance. *Science* 2003; 300: 1140–1142.
4 Lee HK, Park KS, Cho YM, Lee YY, Pak YK. Mitochondria-based model for fetal origin of adult disease and insulin resistance. *Ann N Y Acad Sci* 2005; 1042: 1–18.
5 Lee YJ, Park KS, Pak YK, Lee HK. The role of mitochondrial DNA in the development of type 2 diabetes caused by fetal malnutrition. *J Nutr Biochem* 2005; 16: 195–204.
6 Lowell BB, Shulman GI. Mitochondrial dysfunction and type 2 diabetes. *Science* 2005; 307: 384–387.
7 Kim JA, Wei Y, Sowers JR. Role of mitochondrial dysfunction in insulin resistance. *Circ Res* 2008; 102: 401–414.
8 Ahn SY, Choi YS, Koo HJ, Jeong JH, Park WH, Kim M et al. Mitochondrial dysfunction enhances the migration of vascular smooth muscles cells via suppression of Akt phosphorylation. *Biochim Biophys Acta* 2010; 1800: 275–281.
9 Petersen KF, Dufour S, Befroy D, Garcia R, Shulman GI. Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes. *N Engl J Med* 2004; 350: 664–671.

10 Chan DC. Mitochondria: dynamic organelles in disease, aging and development. *Cell* 2006; 125: 1241–1252.

11 Kujoth GC, Hiona A, Pugh TD, Someya S, Panzer K, Wohlgemuth SE et al. Mitochondrial DNA mutations, oxidative stress and apoptosis in mammalian aging. *Science* 2005; 309: 481–484.

12 Michikawa Y, Mazzucchelli F, Bresolin N, Scarlato G, Attardi G. Age-dependent large accumulation of point mutations in the human mtDNA control region for replication. *Science* 1999; 286: 774–779.

13 Cardellach F, Gallof J, Cusso R, Urbano-Marquez A. Decline in skeletal muscle mitochondrial respiration chain function with ageing. *Lancer* 1989; 2: 64–45.

14 Koo HJ, Piao Y, Pak YK. Endoplasmic reticulum stress impairs insulin signaling through mitochondrial damage in SH-SY5Y cells. *Neurosignals* 2012; 20: 265–280.

15 Wagner BK, Kitami T, Gilbert TJ, Peck D, Ramanathan A, Schreiber SL et al. Large-scale chemical dissection of mitochondrial function. *Nat Biotechnol* 2008; 26: 343–351.

16 Lim S, Ahn SY, Song IC, Chung MH, Jang HC, Park KS et al. Reduced mitochondrial density and increased IRS-1 serine phosphorylation for miR-145 in pulmonary arterial hypertension: evidence from mouse model. *Circ Res* 2012; 110: 879–889.

17 Morino K, Petersen KF, Dufour S, Befroy D, Frattini J, Shatzkes N et al. Mitochondrial DNA damage and cellular responses to DNA double-strand breaks. *Proc Natl Acad Sci USA* 2011; 108: 205–210.

18 Palmiter RD, O'Shea MM, Zee JS, Liao Y, Cooper DN et al. A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure. *Proc Natl Acad Sci USA* 2006; 103: 18255–18260.

19 Esau C, Kang X, Peralta E, Hansen E, Marcussen EG, Ravichandran LV et al. MicroRNA-143 regulates adipocyte differentiation. *J Biol Chem* 2004; 279: 52361–52365.

20 Gauthier BR, Wollheim CB. MicroRNAs: ‘ribo-regulators’ of glucose homeostasis. *Nat Med* 2006; 12: 36–38.

21 Makeyev EV, Zhang J, Carrasco MA, Maniatis T. The microRNA miR-124 promotes neuronal differentiation by triggering brain-specific alternative pre-mRNA splicing. *Mol Cell* 2007; 27: 435–448.

22 Piao Y, Kim HG, Oh MS, Pak YK. Overexpression of TFAM, NFR-1 and miR-15a protects the heart from MPTP-induced mitochondrial dysfunctions in neuronal cells. *Biochim Biophys Acta* 2012; 1820: 577–585.

23 Williams AH, Liu N, van Rooij E, Olson EN. MicroRNA control of muscle development and disease. *Curr Opin Cell Biol* 2009; 21: 461–469.

24 Pak YK, Weiner H. Import of chemically synthesized signal peptides into rat liver mitochondria. *J Biol Chem* 1990; 265: 14298–14307.

25 Hatley ME, Patrick DM, Garcia MR, Richardson JA, Bassel-Duby R, van Rooij E et al. Modulation of K-Ras-dependent lung tumorigenesis by microRNA-21. *Cancer Cell* 2010; 18: 282–293.

26 van Rooij E, Marshall WS, Olson EN. Toward microRNA-based therapeutics for heart disease: the sense in antisense. *Circ Res* 2008; 103: 919–928.

27 van Rooij E, Liu N, Olson EN. MicroRNAs flex their muscles. *Trends Genet* 2008; 24: 159–166.

28 Challagundla KB, Sun XQ, Zhang X, DeVine T, Zhang Q, Sears RC et al. Ribosomal protein L11 recruits miR-24/miR-34 to repress c-Myc expression in response to ribosomal stress. *Mol Cell Biol* 2011; 31: 4007–4021.

29 Davis RC, Castellani LW, Hosseini M, Ben-Zeev O, Mao HZ, Weinstein MM et al. MicroRNA-143 regulates adipocyte differentiation. *J Biol Chem* 2005; 280: 27318–27327.

30 Alvarez-Garcia I, Miska EA. MicroRNA functions in animal development and human disease. *Development* 2005; 132: 4653–4662.

31 Caruso P, Dempe JH, McDonald RA, Long L, Lu R et al. A role for miR-145 in pulmonary arterial hypertension: evidence from mouse models and patient samples. *Circ Res* 2012; 111: 290–300.

32 Saura RB,神奇 BM, Lanto D, McDonald RA, Long L, Lu R et al. A role for miR-145 in mitochondrial DNA damage response. *Biochem Biophys Res Commun* 2005; 336: 807–812.

33 Lewis BP, Shih IH, Jones-Rhoades MW, Bartel DP, Burge CB. Prediction of mammalian microRNA targets. *Cell* 2003; 115: 787–798.

34 Grueter CE, van Rooij E, Johnson BA, DeLeon SM, Sutherland LB, Qi X et al. A cardiac microRNA governs systemic energy homeostasis by regulation of MED13. *Cell* 2012; 149: 671–683.

35 Montgomery RL, Hullinger TG, Semus HM, Dickinson BA, Seto AG, Lynch JM et al. Therapeutic inhibition of miR-208a improves cardiac function and survival during heart failure. *Circulation* 2011; 124: 1537–1547.

36 Zampetaki A, Kiechl S, Drozdow I, Willett P, Mayr U, Prokop M et al. Plasma microRNA profiling reveals loss of endothelial miR-126 and other microRNAs in type 2 diabetes. *Circ Res* 2010; 107: 810–817.

37 Patrick DM, Montgomery RL, Qi X, Obad S, Kauppinnen S, Hill JA et al. Stress-dependent cardiac remodeling occurs in the absence of microRNA-21 in mice. *J Clin Invest* 2010; 120: 3912–3916.

38 van Rooij E, Sutherland LB, Liu N, Williams AH, McNally J, Gerard RD et al. A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure. *Proc Natl Acad Sci USA* 2006; 103: 18255–18260.
58 Sayed D, Hong C, Chen IY, Abdellatif M. MicroRNAs play an essential role in the development of cardiac hypertrophy. Circ Res 2007; 100: 416–424.

59 Rector RS, Thyfault JP, Uptergrove GM, Morris EM, Naples SP, Borengasser SJ et al. Mitochondrial dysfunction precedes insulin resistance and hepatic steatosis and contributes to the natural history of non-alcoholic fatty liver disease in an obese rodent model. J Hepatol 2010; 52: 727–736.

60 Jordan SD, Kruger M, Willmes DM, Redemann N, Wunderlich FT, Bronneke HS et al. Obesity-induced overexpression of miRNA-143 inhibits insulin-stimulated AKT activation and impairs glucose metabolism. Nat Cell Biol 2011; 13: 434–446.

Supplementary Information accompanies the paper on Experimental & Molecular Medicine website (http://www.nature.com/emm)